RT Journal Article
SR Electronic
T1 Characterising post-COVID syndrome more than 6 months after acute infection in adults; prospective longitudinal cohort study, England
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.18.21253633
DO 10.1101/2021.03.18.21253633
A1 Amin-Chowdhury, Zahin
A1 Harris, Ross J
A1 Aiano, Felicity
A1 Zavala, Maria
A1 Bertran, Marta
A1 Borrow, Ray
A1 Linley, Ezra
A1 Ahmad, Shazaad
A1 Parker, Ben
A1 Horsley, Alex
A1 Hallis, Bassam
A1 Flood, Jessica
A1 Brown, Kevin E
A1 Amirthalingam, Gayatri
A1 Ramsay, Mary E
A1 Andrews, Nick
A1 Ladhani, Shamez N
YR 2021
UL http://medrxiv.org/content/early/2021/04/16/2021.03.18.21253633.abstract
AB Background Most individuals with COVID-19 will recover without sequelae, but some will develop long- term multi-system impairments. The definition, duration, prevalence and symptoms associated with long COVID, however, have not been established.Methods Public Health England (PHE) initiated longitudinal surveillance of clinical and non-clinical healthcare workers for monthly blood sampling for SARS-CoV-2 antibodies in March 2020. Eight months after enrolment, participants completed an online questionnaire including 72 symptoms in the preceding month. Symptomatic mild-to-moderate cases with confirmed COVID-19 were compared with asymptomatic, seronegative controls. Multivariable logistic regression was used to identify independent symptoms associated with long COVID.Results All 2,147 participants were contacted and 1,671 (77.8%) completed the questionnaire, including 140 (8.4%) cases and 1,160 controls. At a median of 7.5 (IQR 7.1-7.8) months after infection, 20 cases (14.3%) had ongoing (4/140, 2.9%) or episodic (16/140, 11.4%) symptoms. We identified three clusters of symptoms associated with long COVID, those affecting the sensory (ageusia, anosmia, loss of appetite and blurred vision), neurological (forgetfulness, short-term memory loss and confusion/brain fog) and cardiorespiratory (chest tightness/pain, unusual fatigue, breathlessness after minimal exertion/at rest, palpitations) systems. The sensory cluster had the highest association with being a case (aOR 5.25, 95% CI 3.45-8.01). Dermatological, gynaecological, gastrointestinal or mental health symptoms were not significantly different between cases and controls.Conclusions Most persistent symptoms reported following mild COVID-19 were equally common in cases and controls. While all three clusters identified had a strong association with previous COVID-19 infection, the sensory cluster had the highest specificity and strength of association.Key points Compared to controls, we identified three clusters of symptoms affecting the sensory, neurological and cardiorespiratory systems that were more prevalent among cases. Notably, gastrointestinal and dermatological symptoms and symptoms related to mental health were as prevalent among cases as controls.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was internally funded by Public Health England with additional support provided by the NIHR Manchester Clinical Research Facility. The study was also carried out at the NIHR Manchester Clinical Research Facility. AH and BP are supported by the NIHR Manchester Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NGS, the NIHR, of the Department of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by PHE Research & Public Health Practice Ethics and Governance Group (R&D REGG Ref NR 0190).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData not available due to ethical restrictions